NeuroBo Pharmaceuticals to Participate in Investor Conferences in October

Rhea-AI Summary

NeuroBo Pharmaceuticals, a clinical-stage biotechnology company focused on cardiometabolic diseases, announced its participation in two investor conferences in October 2024:

1. H.C. Wainwright 8th Annual MASH Virtual Conference on October 7: President and CEO Hyung Heon Kim will present a company overview at 11:00 am ET. Management will be available for one-on-one meetings.

2. 2024 Maxim Healthcare Virtual Summit from October 15-17: Kim and CFO Marshall H. Woodworth will participate in a virtual fireside chat on October 15 at 2:30 pm ET.

Investors can register for the H.C. Wainwright conference at https://hcwevents.com/mashconference/. To schedule meetings outside these conferences, contact Michael Miller at mmiller@rxir.com.

CAMBRIDGE, Mass., Oct. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October:

• October 7: H.C. Wainwright 8^th Annual MASH Virtual Conference. Hyung Heon Kim, President and Chief Executive Officer, will present a company overview on Monday, October 7, at 11:00 am ET.
  
  Management will also be available for one-on-one meetings during the event. Individuals who would like to listen to the Company's presentation or request a meeting can do so after registering for the conference at https://hcwevents.com/mashconference/.
  
  
• October 15-17: 2024 Maxim Healthcare Virtual Summit. Mr. Kim and Marshall H. Woodworth, Chief Financial Officer, will participate in a virtual fireside chat hosted by Jason McCarthy, Ph.D., senior managing director, head of biotechnology research at Maxim Group, on Tuesday, October 15, at 2:30 pm ET.

To schedule a meeting with management outside of these conferences, investors can contact Michael Miller at mmiller@rxir.com.

About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visit www.neurobopharma.com.

Contacts:

NeuroBo Pharmaceuticals
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@neurobopharma.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

 

View original content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-to-participate-in-investor-conferences-in-october-302263743.html

SOURCE NeuroBo Pharmaceuticals, Inc.

FAQ

What investor conferences will NeuroBo Pharmaceuticals (NRBO) attend in October 2024?

NeuroBo Pharmaceuticals will attend the H.C. Wainwright 8th Annual MASH Virtual Conference on October 7 and the 2024 Maxim Healthcare Virtual Summit from October 15-17.

Who will represent NeuroBo Pharmaceuticals (NRBO) at these investor conferences?

Hyung Heon Kim, President and CEO, will present at the H.C. Wainwright conference. Kim and Marshall H. Woodworth, CFO, will participate in a fireside chat at the Maxim Healthcare Virtual Summit.

When is NeuroBo Pharmaceuticals' (NRBO) presentation at the H.C. Wainwright conference?

NeuroBo Pharmaceuticals' presentation at the H.C. Wainwright conference is scheduled for Monday, October 7, 2024, at 11:00 am ET.

How can investors register for NeuroBo Pharmaceuticals' (NRBO) presentation at the H.C. Wainwright conference?

Investors can register for the H.C. Wainwright conference and NeuroBo Pharmaceuticals' presentation at https://hcwevents.com/mashconference/.

How can investors schedule meetings with NeuroBo Pharmaceuticals (NRBO) management outside of these conferences?

Investors can schedule meetings with NeuroBo Pharmaceuticals management outside of these conferences by contacting Michael Miller at mmiller@rxir.com.